Brii Biosciences Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	18.61	-	0.62	51.63	-
Other Revenue	16.94	49.94	55.27	70.65	92.54
Revenue	35.55	49.94	55.89	122.28	92.54
Revenue Growth (YoY)	-28.81%	-10.66%	-54.29%	32.13%	12.56%
Gross Profit	35.55	49.94	55.89	122.28	92.54
Selling, General & Admin	109.45	153.16	197.92	195.49	208.4
Research & Development	212.9	249.85	402.71	440.63	494.62
Operating Expenses	322.35	453.79	600.62	636.12	703.02
Operating Income	-286.8	-403.85	-544.73	-513.85	-610.48
Interest Expense	-1.96	-2.37	-0.49	-0.85	-1.18
Interest & Investment Income	51.54	87.15	108.02	37.2	6.49
Currency Exchange Gain (Loss)	1.9	1.67	121.59	-43.98	0.27
Other Non Operating Income (Expenses)	-0.42	5.06	0.43	-	-
EBT Excluding Unusual Items	-235.75	-312.34	-315.18	-521.47	-604.9
Gain (Loss) on Sale of Investments	13.99	-109.69	136.24	31.69	44.8
Gain (Loss) on Sale of Assets	-0.41	-	-	-	-
Asset Writedown	-	-90.35	-5.43	-	-
Other Unusual Items	-	-	-	-	-3,631
Pretax Income	-222.17	-512.38	-184.37	-489.78	-4,191
Income Tax Expense	1.9	-	-	-	-
Earnings From Continuing Operations	-224.07	-512.38	-184.37	-489.78	-4,191
Minority Interest in Earnings	1.44	4.22	9.54	5.47	27.24
Net Income	-222.62	-508.16	-174.83	-484.31	-4,164
Net Income to Common	-222.62	-508.16	-174.83	-484.31	-4,164
Shares Outstanding (Basic)	722	730	728	723	439
Shares Outstanding (Diluted)	722	730	728	723	439
Shares Change (YoY)	-1.15%	0.29%	0.64%	64.78%	129.57%
EPS (Basic)	-0.31	-0.70	-0.24	-0.67	-9.48
EPS (Diluted)	-0.31	-0.70	-0.24	-0.67	-9.48
Free Cash Flow	-340.46	-376.12	-594.01	-496.28	-880.49
Free Cash Flow Per Share	-0.47	-0.52	-0.82	-0.69	-2.00
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-806.80%	-808.74%	-974.63%	-420.22%	-659.68%
Profit Margin	-626.26%	-1017.63%	-312.80%	-396.07%	-4499.41%
Free Cash Flow Margin	-957.76%	-753.20%	-1062.81%	-405.86%	-951.45%
EBITDA	-286.14	-401.61	-538.15	-505.9	-602.8
D&A For EBITDA	0.66	2.25	6.59	7.94	7.68
EBIT	-286.8	-403.85	-544.73	-513.85	-610.48

Source: S&P Global Market Intelligence. Standard template. Financial Sources.